CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): Mouse background determines the effect of FcγRIIb genetic disruption

Transfusion

Volumn 55, Issue 6, 2015, Pages 1492-1500

  Crow, Andrew R ^a,b,c   Amash, Alaa ^b,c   Lazarus, Alan H ^a,b,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE ANTIBODY; FC RECEPTOR IIB; HERMES ANTIGEN; THROMBOCYTE ANTIBODY; ANTIBODY; CD44 PROTEIN, MOUSE; FC RECEPTOR; FCGR2B PROTEIN, MOUSE; IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; GENE DISRUPTION; IMMUNE THROMBOCYTOPENIA; MACROPHAGE; MOUSE; NONHUMAN; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANIMAL; C3H MOUSE; C57BL MOUSE; DISEASE MODEL; GENE TARGETING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SCID MOUSE; SPECIES DIFFERENCE;

ANIMALS; ANTIBODIES; ANTIGENS, CD44; DISEASE MODELS, ANIMAL; GENE TARGETING; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; SPECIES SPECIFICITY;

EID: 84931565348     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12957     Document Type: Article

References (56)

1. Crow AR, Song S, Suppa SJ, et al. Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP? Blood 2011; 117: 971-974.
2. Song S, Crow AR, Freedman J, et al. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003; 101: 3708-3713.
3. Bazin R, Lemieux R, Tremblay T, et al. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 2004; 127: 90-96.
4. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010; 115: 1247-1253.
5. Crow AR, Song S, Semple JW, et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001; 115: 679-686.
6. Crow AR, Song S, Semple JW, et al. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 2007; 109: 155-158.
7. Crow AR, Yu H, Han D, et al. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway. PLoS ONE 2013; 8: e71882.
8. Deng R, Balthasar JP,. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood 2007; 109: 2470-2476.
9. Katsman Y, Foo AH, Leontyev D, et al. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Transfusion 2010; 50: 1285-1294.
10. Samuelsson A, Towers TL, Ravetch JV,. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486.
11. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095-1099.
12. Siragam V, Brinc D, Crow AR, et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005; 115: 155-160.
13. Mikecz K, Brennan FR, Kim JH, et al. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1995; 1: 558-563.
14. Mott PJ, Lazarus AH,. CD44 antibodies and immune thrombocytopenia in the amelioration of murine inflammatory arthritis. PLoS ONE 2013; 8: e65805.
15. Nedvetzki S, Walmsley M, Alpert E, et al. CD44 involvement in experimental collagen-induced arthritis (CIA). J Autoimmun 1999; 13: 39-47.
16. Bruhns P, Samuelsson A, Pollard JW, et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18: 573-581.
17. Bruley-Rosset M, Mouthon L, Chanseaud Y, et al. Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases. Lab Invest 2003; 83: 1013-1023.
18. Brennan FR, O'Neill JK, Allen SJ, et al. CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease. Immunology 1999; 98: 427-435.
19. Humle Jorgensen S, Sorensen PS,. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci 2005; 233: 61-65.
20. Shintani N, Nakajima T, Nakakubo H, et al. Intravenous immunoglobulin (IVIG) treatment of experimental colitis induced by dextran sulfate sodium in rats. Clin Exp Immunol 1997; 108: 340-345.
21. Wittig B, Schwarzler C, Fohr N, et al. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J Immunol 1998; 161: 1069-1073.
22. Inoue Y, Kaifu T, Sugahara-Tobinai A, et al. Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. J Immunol 2007; 179: 764-774.
23. Weiss L, Slavin S, Reich S, et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc Natl Acad Sci U S A 2000; 97: 285-290.
24. Katoh S, Matsumoto N, Kawakita K, et al. A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest 2003; 111: 1563-1570.
25. Araujo LM, Chauvineau A, Zhu R, et al. Cutting edge: intravenous Ig inhibits invariant NKT cell-mediated allergic airway inflammation through FcgammaRIIIA-dependent mechanisms. J Immunol 2011; 186: 3289-3293.
26. Zhu KY, Feferman T, Maiti PK, et al. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J Neuroimmunol 2006; 176: 187-197.
27. Saoudi A, Hurez V, de Kozak Y, et al. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 1993; 5: 1559-1567.
28. Obrador E, Peinado E, de Kozak Y, et al. Human immunoglobulin preparations for intravenous use prevent endotoxin-induced uveitis in rats. Ophthalmic Res 1999; 31: 59-67.
29. Wada J, Shintani N, Kikutani K, et al. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin Exp Immunol 2001; 124: 282-289.
30. Gabriel CM, Gregson NA, Redford EJ, et al. Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 1997; 120 (Pt 9): 1533-1540.
31. Parish NM, Brennan FR, Cooke A,. Anti-CD44 treatment does not prevent the extravasation of autopathogenic T cells to the thyroid in experimental autoimmune thyroiditis. Immunology 1999; 97: 533-539.
32. Crow AR, Song S, Freedman J, et al. IVIg-mediated amelioration of murine ITP via Fc{gamma}RIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003; 102: 558-560.
33. Leontyev D, Katsman Y, Branch DR,. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcgamma receptor for the amelioration of experimental ITP. Blood 2012; 119: 5261-5264.
34. Schwab I, Biburger M, Kronke G, et al. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 2012; 42: 826-830.
35. Bussel JB, Pham LC,. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987; 52: 206-211.
36. Bazin R, Lemieux R, Tremblay T,. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135: 97-100.
37. Song S, Crow AR, Siragam V, et al. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005; 105: 1546-1548.
38. Arnson Y, Shoenfeld Y, Amital H,. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009; 42: 553-560.
39. Hartung HP,. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255 (Suppl 3): 3-6.
40. Schwab I, Nimmerjahn F,. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013; 13: 176-189.
41. Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608-615.
42. Crow AR, Brinc D, Lazarus AH,. New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost 2009; 7 (Suppl 1): 245-248.
43. Imbach P, Lazarus AH, Kuhne T,. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang 2010; 98: 385-394.
44. Leontyev D, Katsman Y, Ma XZ, et al. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; 52: 1799-1805.
45. Shimomura M, Hasegawa S, Seki Y, et al. Intravenous immunoglobulin does not increase FcgammaRIIB expression levels on monocytes in children with immune thrombocytopenia. Clin Exp Immunol 2012; 169: 33-37.
46. Ichiyama T, Ueno Y, Hasegawa M, et al. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease. Rheumatology (Oxford) 2005; 44: 314-317.
47. Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fc{gamma} receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106: 4788-4792.
48. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcgammaRIII controlling inflammatory responses. Blood 2012; 119: 3084-3096.
49. Machino Y, Ohta H, Suzuki E, et al. Effect of immunoglobulin G (IgG) interchain disulfide bond cleavage on efficacy of intravenous immunoglobulin for immune thrombocytopenic purpura (ITP). Clin Exp Immunol 2010; 162: 415-424.
50. Crow AR, Suppa SJ, Chen X, et al. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Blood 2011; 118: 6403-6406.
51. Cardo LJ, Strack M, Williams J,. Anti-D for the treatment of splenectomized patients with immune thrombocytopenic purpura. Blood 1991; 78: 2786-2787.
52. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89: 2689-2700.
53. Ramadan KM, El-Agnaf M,. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin Lab Haematol 2005; 27: 267-269.
54. Bussel J,. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 2006; 43: S3-10; discussion S8-9.
55. Cheung E, Liebman HA,. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics 2009; 3: 57-62.
56. Othy S, Hegde P, Topcu S, et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol 2013; 190: 4535-4541.